Equities research analysts expect that TG Therapeutics Inc (NASDAQ:TGTX) will announce earnings per share of ($0.46) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for TG Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.52). TG Therapeutics reported earnings per share of ($0.33) in the same quarter last year, which suggests a negative year over year growth rate of 39.4%. The business is scheduled to report its next quarterly earnings results on Monday, August 14th.

According to Zacks, analysts expect that TG Therapeutics will report full-year earnings of ($1.83) per share for the current fiscal year, with EPS estimates ranging from ($2.11) to ($1.45). For the next financial year, analysts anticipate that the business will post earnings of ($1.74) per share, with EPS estimates ranging from ($2.06) to ($1.17). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. TG Therapeutics had a negative net margin of 47,494.08% and a negative return on equity of 83.18%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million.

A number of brokerages have recently weighed in on TGTX. Zacks Investment Research upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 15th. FBR & Co restated an “outperform” rating and issued a $26.00 target price (up previously from $24.00) on shares of TG Therapeutics in a research note on Monday, March 6th. Ladenburg Thalmann Financial Services set a $30.00 target price on TG Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, March 8th. Raymond James Financial, Inc. restated a “buy” rating on shares of TG Therapeutics in a research note on Friday, April 21st. Finally, SunTrust Banks, Inc. set a $28.00 target price on TG Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 13th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. TG Therapeutics has an average rating of “Buy” and an average price target of $23.17.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/05/26/tg-therapeutics-inc-tgtx-expected-to-announce-earnings-of-0-46-per-share.html.

TG Therapeutics (NASDAQ:TGTX) traded up 1.26% during mid-day trading on Friday, hitting $12.05. The stock had a trading volume of 1,255,781 shares. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.05. The firm’s 50-day moving average price is $10.91 and its 200-day moving average price is $7.69. The stock’s market cap is $742.95 million.

In other TG Therapeutics news, Director Laurence N. Charney sold 7,000 shares of the business’s stock in a transaction on Tuesday, April 4th. The shares were sold at an average price of $11.17, for a total transaction of $78,190.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William James Kennedy sold 8,548 shares of the business’s stock in a transaction on Tuesday, April 11th. The shares were sold at an average price of $10.27, for a total transaction of $87,787.96. The disclosure for this sale can be found here. Insiders own 19.00% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Baker BROS. Advisors LP purchased a new position in TG Therapeutics during the third quarter valued at $15,511,000. North Star Investment Management Corp. boosted its position in TG Therapeutics by 110.0% in the first quarter. North Star Investment Management Corp. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 11,000 shares during the last quarter. Guggenheim Capital LLC boosted its position in TG Therapeutics by 67.6% in the fourth quarter. Guggenheim Capital LLC now owns 267,985 shares of the biopharmaceutical company’s stock valued at $1,246,000 after buying an additional 108,106 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in TG Therapeutics during the fourth quarter valued at $143,000. Finally, Creative Planning boosted its position in TG Therapeutics by 3.2% in the first quarter. Creative Planning now owns 32,001 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 1,000 shares during the last quarter. 50.08% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

12 Month Chart for NASDAQ:TGTX

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TG Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.